[PDF] Top 20 Informe Ecuacion de Cantidad de Movimiento

... intravenous temsirolimus 25mg as an intravenous infusion over no less than 30 minutes but with completion of infusion within 60 ...of temsirolimus or when the drug had to withdrawn due to ... See full document

... small retrospective analysis of adverse events experienced in 32 patients as a result of sunitinib treatment versus response, Rixe et al reported that only the occurrence or worsening of hypertension ... See full document

... this retrospective analysis, we reviewed patients with mRCC treated with EV or TM after first-line SU in the main centres involved in kidney cancer treatment in ...included patients ... See full document

... the patients in this study. The trial showed that the patients randomized to receive temsirolimus had a median survival of ...the patients receiving interferon- a alone (hazard ratio [HR] = ... See full document

... AEs. Patients were treated until progression, although this assumption was tested in a sensitivity analysis. The drug acquisition cost for 10 mg/mL nivolumab was $US2545.15 per vial for 100 mg, and ... See full document

... 20 patients with RCC- related venous thrombus in the retrohepatic portion of the inferior vena cava (IVC) underwent surgical thromb- ...been treated in our department 5 years earlier, with nephrectomy and ... See full document

... subgroup analysis of the previous phase II trial of ipi- limumab evaluated the onset of other autoimmune- related AEs in the cohort of 61 patients with metastatic ...of patients experienced a grade 3 ... See full document

... Patients previously receiving local therapy (eg, surgery, radiation, hepatic artery embolization, TACE, RFA, percuta- neous ethanol injection, or cryoablation) were eligible under following conditions: local ... See full document

... mTORs temsirolimus and everolimus) have been introduced and are now approved for clinical use [3, 6, ...for advanced RCC primarily in the western population [7, ...tivozanib, temsirolimus, AMG 386, ... See full document

... of patients with ECOG PS = 2, often excluded by Phase III trials, with the consequent advantage for cabozantinib of being the only drug with tangible data in this ...PAREXEL analysis, data on 38 ... See full document

... for patients with advanced ...identify patients with poor prognosis. While patients with poor risk features have a more limited outcome, treatment with temsirolimus has led to ... See full document

... of advanced and metastatic renal cell carcinoma (mRCC) treated with targeted therapy differs between young and old ...patients. Patients and methods: A total of 327 ... See full document

... twenty-one patients were stratified to receive either nivolumab or everolimus with a primary endpoint of ...nivolumab-treated patients reported grade 3 or 4 treatment-related adverse effects compared ... See full document

... of patients experienced grade 3/ 4 toxicities, and treatment modifications occurred in 50 – 55% patients because of adverse ...20% patients discontinued TKI therapy because of adverse events [1, 2, ... See full document

... clear cell, papillary, chromophobe, and other rarer ...in advanced RCC and have changed the standard of care in this disease ...in patients with clear cell histol- ...mast/stem cell ... See full document

... 38 patients with metastatic RCC who were treated with temsirolimus within a compassionate use ...with temsirolimus ahead of marketing authorization to patients who might derive a ... See full document

... NSCLC patients with EGFR mutation and who received EGFR-TKIs ...NSCLC patients who received EGFR-TKIs as the first-line ...benefits treated with bisphosphonates and EGFR-TKIs in some malignancies ... See full document

... the patients was done according to con- sideration of nephrectomy ...nephrectomized patients were included with metachronous or synchronous metatastic ...regression analysis to identify the factors ... See full document

... our analysis we showed how a different pattern of expression of polymorphisms leads to a different outcome according to the first-line drug ...in patients with better outcome with sunitinib or ...sunitinib ... See full document

... Locally advanced RCC remains a challenge for ...our patients can be used to select patients for whom novel therapeutic agents can potentially play a ...Many patients with tumour thrombus ... See full document